A S Carr1, A L Pelayo-Negro2, M Rb Evans1, M Laurà1, J Blake3, C Stancanelli4, V Iodice4, A D Wechalekar5, C J Whelan5, J D Gillmore5, P N Hawkins5, M M Reilly1. 1. MRC Centre for Neuromuscular Diseases, UCL Institute of Neurology, London, UK. 2. MRC Centre for Neuromuscular Diseases, UCL Institute of Neurology, London, UK Department of Neurology, University Hospital "Marqués de Valdecilla", Santander, Spain. 3. MRC Centre for Neuromuscular Diseases, UCL Institute of Neurology, London, UK Department of Clinical Neurophysiology, Norfolk and Norwich University Hospital, Norwich, UK. 4. Autonomic unit, National Hospital of Neurology and Neurosurgery, London, UK. 5. National Amyloidosis Centre, University College London Medical School, Royal Free Campus, London, UK.
Abstract
BACKGROUND: Hereditary transthyretin amyloidosis (ATTR) is usually characterised by a progressive peripheral and autonomic neuropathy often with associated cardiac failure and is due to dominantly inherited transthyretin mutations causing accelerated amyloid deposition. The UK population is unique in that the majority of patients have the T60A missense mutation in ATTR where tyrosine is replaced by adenine at position 60. This has been traced to a single founder mutation from north-west Ireland. The neuropathy phenotype is less well described than the cardiac manifestations in this group. METHODS: We present the findings from an observational cohort study of patients with ATTR attending the National Hospital Inherited Neuropathy Clinic between 2009 and 2013. Detailed clinical neurological and electrophysiological data were collected on all patients alongside correlating autonomic and cardiac assessments. Follow-up data were available on a subset. RESULTS: Forty-four patients with genetically confirmed ATTR were assessed; 37 were symptomatic; mean age at onset=62 years, range=38-75 years; 75.7% male. T60A was the most common mutation (17/37), followed by V30M (5/37). A severe, rapidly progressive, predominantly length dependent axonal sensorimotor neuropathy was the predominant phenotype. T60A patients were distinguished by earlier and more frequent association with carpal tunnel syndrome; a predominance of negative sensory symptoms at onset; significant vibration deficits; and a non-length dependent progression of motor deficit. Progression of the neuropathy was observed over a relatively short follow-up period (2 years) in 20 patients with evidence of clinically measurable annual change in Medical Research Council (MRC) sum score (-1.5 points per year) and Charcot Marie Tooth Neuropathy Score (CMTNS:2.7 points per year), and a congruent trend in the electrophysiological measures used. CONCLUSION: The description of the ATTR neuropathy phenotype, especially in the T60A patients, should aid early diagnosis as well as contribute to the understanding of its natural history. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
BACKGROUND: Hereditary transthyretin amyloidosis (ATTR) is usually characterised by a progressive peripheral and autonomic neuropathy often with associated cardiac failure and is due to dominantly inherited transthyretin mutations causing accelerated amyloid deposition. The UK population is unique in that the majority of patients have the T60A missense mutation in ATTR where tyrosine is replaced by adenine at position 60. This has been traced to a single founder mutation from north-west Ireland. The neuropathy phenotype is less well described than the cardiac manifestations in this group. METHODS: We present the findings from an observational cohort study of patients with ATTR attending the National Hospital Inherited Neuropathy Clinic between 2009 and 2013. Detailed clinical neurological and electrophysiological data were collected on all patients alongside correlating autonomic and cardiac assessments. Follow-up data were available on a subset. RESULTS: Forty-four patients with genetically confirmed ATTR were assessed; 37 were symptomatic; mean age at onset=62 years, range=38-75 years; 75.7% male. T60A was the most common mutation (17/37), followed by V30M (5/37). A severe, rapidly progressive, predominantly length dependent axonal sensorimotor neuropathy was the predominant phenotype. T60A patients were distinguished by earlier and more frequent association with carpal tunnel syndrome; a predominance of negative sensory symptoms at onset; significant vibration deficits; and a non-length dependent progression of motor deficit. Progression of the neuropathy was observed over a relatively short follow-up period (2 years) in 20 patients with evidence of clinically measurable annual change in Medical Research Council (MRC) sum score (-1.5 points per year) and Charcot Marie Tooth Neuropathy Score (CMTNS:2.7 points per year), and a congruent trend in the electrophysiological measures used. CONCLUSION: The description of the ATTR neuropathy phenotype, especially in the T60A patients, should aid early diagnosis as well as contribute to the understanding of its natural history. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
Authors: Thomas H Brannagan; Michaela Auer-Grumbach; John L Berk; Chiara Briani; Vera Bril; Teresa Coelho; Thibaud Damy; Angela Dispenzieri; Brian M Drachman; Nowell Fine; Hanna K Gaggin; Morie Gertz; Julian D Gillmore; Esther Gonzalez; Mazen Hanna; David R Hurwitz; Sami L Khella; Mathew S Maurer; Jose Nativi-Nicolau; Kemi Olugemo; Luis F Quintana; Andrew M Rosen; Hartmut H Schmidt; Jacqueline Shehata; Marcia Waddington-Cruz; Carol Whelan; Frederick L Ruberg Journal: Orphanet J Rare Dis Date: 2021-05-06 Impact factor: 4.123
Authors: Antonia Carroll; P James Dyck; Mamede de Carvalho; Marina Kennerson; Mary M Reilly; Matthew C Kiernan; Steve Vucic Journal: J Neurol Neurosurg Psychiatry Date: 2022-03-07 Impact factor: 13.654
Authors: Andrea Cortese; Yi Zhu; Adriana P Rebelo; Sara Negri; Steve Courel; Lisa Abreu; Chelsea J Bacon; Yunhong Bai; Dana M Bis-Brewer; Enrico Bugiardini; Elena Buglo; Matt C Danzi; Shawna M E Feely; Alkyoni Athanasiou-Fragkouli; Nourelhoda A Haridy; Rosario Isasi; Alaa Khan; Matilde Laurà; Stefania Magri; Menelaos Pipis; Chiara Pisciotta; Eric Powell; Alexander M Rossor; Paola Saveri; Janet E Sowden; Stefano Tozza; Jana Vandrovcova; Julia Dallman; Elena Grignani; Enrico Marchioni; Steven S Scherer; Beisha Tang; Zhiqiang Lin; Abdullah Al-Ajmi; Rebecca Schüle; Matthis Synofzik; Thierry Maisonobe; Tanya Stojkovic; Michaela Auer-Grumbach; Mohamed A Abdelhamed; Sherifa A Hamed; Ruxu Zhang; Fiore Manganelli; Lucio Santoro; Franco Taroni; Davide Pareyson; Henry Houlden; David N Herrmann; Mary M Reilly; Michael E Shy; R Grace Zhai; Stephan Zuchner Journal: Nat Genet Date: 2020-05-04 Impact factor: 41.307
Authors: Teresa Coelho; Giampaolo Merlini; Christine E Bulawa; James A Fleming; Daniel P Judge; Jeffery W Kelly; Mathew S Maurer; Violaine Planté-Bordeneuve; Richard Labaudinière; Rajiv Mundayat; Steve Riley; Ilise Lombardo; Pedro Huertas Journal: Neurol Ther Date: 2016-02-19
Authors: Imad Bentellis; Gérard Amarenco; Xavier Gamé; Dora Jericevic; Mehdi El-Akri; Caroline Voiry; Lucas Freton; Juliette Hascoet; Quentin Alimi; Jacques Kerdraon; Benjamin M Brucker; Benoit Peyronnet Journal: Clin Auton Res Date: 2019-08-26 Impact factor: 4.435